key: cord-0682562-9x5os5jr
authors: Fareh, Mohamed; Zhao, Wei; Hu, Wenxin; Casan, Joshua ML; Kumar, Amit; Symons, Jori; Voskoboinik, Ilia; Ekert, Paul G; Rudraraju, Rajeev; Lewin, Sharon R; Trapani, Joseph A
title: Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance
date: 2020-11-19
journal: bioRxiv
DOI: 10.1101/2020.11.18.389312
sha: d78ffca28c92c30931a1f4b9ba617cb6da286ac4
doc_id: 682562
cord_uid: 9x5os5jr

Mutation-driven evolution of SARS coronavirus-2 (SARS-CoV-2) highlights the need for innovative approaches that simultaneously suppress viral replication and circumvent viral escape routes from host immunity and antiviral therapeutics. Here, we employed genome-wide computational prediction and singlenucleotide resolution screening to reprogram CRISPR-Cas13b against SARS-CoV-2 genomic and subgenomic RNAs. Reprogrammed Cas13b effectors targeting accessible regions of Spike and Nucleocapsid transcripts achieved >98% silencing efficiency in virus free-models. Further, optimized and multiplexed gRNAs suppressed viral replication by up to 90% in mammalian cells infected with replication-competent SARS-CoV-2. Unexpectedly, the comprehensive mutagenesis of guide-target interaction demonstrated that single-nucleotide mismatches do not impair the capacity of a potent single gRNA to simultaneously suppress ancestral and mutated SARS-CoV-2 in infected mammalian cells, including the highly infectious and globally disseminated Spike D614G mutant. The specificity, efficiency and rapid deployment properties of reprogrammed Cas13b described here provide a molecular blueprint of antiviral therapeutics to simultaneously suppress a wide range of SARS-CoV-2 mutants, and is readily adaptable to other emerging pathogenic viruses.

ABSTRACT: Mutation-driven evolution of SARS coronavirus-2 (SARS-CoV-2) 27 highlights the need for innovative approaches that simultaneously suppress viral 28 replication and circumvent viral escape routes from host immunity and antiviral 29 therapeutics. Here, we employed genome-wide computational prediction and single- The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 72

Cas13 is a form of bacterial adaptive immunity that suppresses bacteriophage RNA 16-73 efficient degradation of viral RNA (Figure 1D & 1E) . This very low IC50 value also 123 highlights the need for intracellular delivery of just a few copies of gRNA template 124 plasmid to achieve effective silencing, thanks to intracellular gRNA amplification by 125 the transcription machinery. 126

Like all RNA-guided nucleases, pspCas13b specificity is conferred by base-127 pairing between the target and gRNA spacer sequences [26] [27] [28] . Evaluating the tolerance 128 for mismatches in this interaction is therefore critical to determining both the potential 129 off-target activity of pspCas13b (ie, silencing cellular transcripts), and more 130 importantly, the loss of activity against variant sequences generated by the RdRP 131 during viral replication 29, 30 . Given that pspCas13b specificity is still poorly understood, 132

we opted to determine the degree of variation in base-pairing between target RNA and 133 the spacer of gRNA2 that could be tolerated and still lead to RNA degradation. We 134 designed and cloned 9 constructs that encoded successive 3-, 6-, or 9-nt substitutions 135 across the whole gRNA2 spacer sequence ( Figure 1F ). The nucleotide substitutions 136 created mismatches (MSM) that perturbed the thermodynamic stability of the RNA-137 RNA duplex. While a 3-nt mismatches placed internally (position 14-16) or at the 3'end 138 (position 28-30) had minimal impact, 3-nt mismatches at the 5'end reduced the 139 silencing efficacy by ~50%. By comparison, 6-nt mismatches introduced at various 140 locations markedly and consistently reduced silencing, and 9-nt mismatches 141 completely abolished the degradation of the Spike transcript ( Figure 1F) . Taken 142 together, this experiment indicated that gRNA2 requires >21-nt base-pairing with its 143 target to trigger the necessary CRISPR-Cas conformational change and nuclease 144 activation necessary for target degradation 26-28 . Conversely, the ability of pspCas13b 145 to tolerate up to 3-nt mismatches underlines its potential to remain effective against 146 the majority of variants with single-nucleotide polymorphisms in the target sequence, 147 conferring protection against potential viral escape mutants such as the D614G 148 mutation in the SARS-CoV-2 Spike protein 8 , and mutations that compromise the 149 efficacy of therapeutic antibodies against SARS-CoV2 7 . 150

Next, we questioned whether the RNA target sequence and structure may 151 influence pspCas13b silencing efficiency. To comprehensively evaluate this 152 possibility, we generated 61 single-nucleotide-tiled gRNAs covering the 5' and 3' 153 overhangs of the gRNA2 target sequence ( Figure 1G ). This approach generated 154 single-nucleotide resolution of the RNA landscape that influences pspCas13b 155 silencing. Overall, 95% of gRNAs achieved >50% degradation efficiency, and 70% of 156 gRNAs achieved >75% degradation of the Spike transcript. Notably, the least effective 157 gRNAs were spatially clustered, suggesting that the RNA secondary structure and/or 158 the presence of endogenous RNA binding proteins might limit spatial RNA 159 accessibility. The tiling approach employed results in continuous changes in spacer 160 flanking sequences (PFS). Accordingly, our findings revealed that unlike other 161 CRISPR subtypes, pspCas13b activity appears to be independent of defined PFS or 162 PAM-like (protospacer adjacent motif) motifs that constrain the targeting spectrum of 163 other CRISPR effectors 31 . These data highlight the high likelihood of efficient silencing 164 with various pspCas13b gRNAs and emphasize the flexibility of this RNA silencing tool 165 for SARS-CoV-2 suppression. 166

Silencing SARS-CoV-2 nucleocapsid transcript. We next examined whether other 167 SARS-CoV-2 structural components essential for viral assembly can be silenced by 168 pspCas13b. We chose to target the RNA encoding the nucleocapsid protein (NCP) 169 that is critical for viral particle assembly by packaging the RNA genome within the viral 170 envelope 32,33 . Based on the reference genome sequence 23 we designed and cloned 171 the original sequence of the NCP into a reporter vector in frame with a monomeric red 172 replication by pspCas13b is likely explained by a combination of a high viral load (0.1 248 MOI) that saturates intracellular pspCas13b nucleoproteins, and the limited 249 transfection efficiency in VERO cells (25-40%) (Suppl. Figure 3) The emergence of new viral strains of SARS-CoV-2, potentially with enhanced 262 fitness, poses a formidable challenge to any single antiviral or antibody therapy 7 . 263

Likewise, targeting SARS-CoV-2 with a single gRNA may have limited efficacy due to 264 viral adaptation and/or poor accessibility to viral RNA in vivo due to intrinsic RNA 265 folding and/or interference from RNA-binding proteins. We postulated that 266 simultaneously targeting several regions of SARS-CoV-2 viral RNAs with multiplexed 267 gRNAs would mitigate these effects, and reduce the likelihood of viral adaptation. We To the best of our knowledge, this is the first study that definitively demonstrates 282 the effective and specific targeting of replication-competent SARS-CoV-2 in infected 283 mammalian cells, using CRISPR-Cas13. 284 pspCas13b suppresses mutation-driven SARS-CoV-2 evolution. 285

A single nucleotide substitution in the receptor binding domain (RBD) of the Spike 286 protein led to the global emergence of SARS-CoV-2 D614G variant with increased 287 ACE-2 affinity and infective potential 8,9 . Based on the single-nucleotide mismatch data 288 described above (Figure 3A &3B ), we hypothesized that gRNAs designed against 289

ancestral Spike D614 genomic sequence should remain effective against the D614G 290 mutant RNAs despite a single-nucleotide mismatch at the spacer-target interface. To 291 test this, we cloned part of the D614G Spike coding sequence (1221 bp; D614G 292 SARS-CoV-2 genomic region between 22,760-23,980) into the mcherry reporter 293 system, and assessed the silencing efficiency of 6 tiled gRNAs targeting this frequently 294 mutated hotspot. The spacer sequences of all 6 tiled gRNAs tested are designed to 295 fully match the ancestral Spike sequence (D614) and harbour one nucleotide 296 mismatch with the Spike transcript of D614G mutant at spacer positions 5, 10, 15, 20, 297 25, and 30 ( Figure 5A) . The data showed that all 6 gRNAs significantly degraded the 298 D614G mutant transcript (P<0.0001). Interestingly, gRNAs with a single-nucleotide 299 mismatch at spacer position 15, 20, 25, or 30 were highly effective and exhibited >98% 300 silencing efficiency against the D614G mutant transcript. By contrast, gRNAs with a 301 mismatch at position 5 or 10 showed a reduced silencing efficiency estimated at 302 approximatively 85-88% removal of the D614G mutant transcript ( Figure 5A) . These 303 data suggest that pspCas13 and the D614G targeting gRNAs with a single-nucleotide 304 mismatch at positions 15, 20, 25, and 30 are likely to remain effective against both 305 ancestral and D614G mutant in infected cells. Thus, the mismatch tolerance molecular 306 mechanism described here is expected to confer pspCas13d resilience against 307 spontaneous single-nucleotide mutations that drive viral escape in SARS-CoV-2 and 308 other pathogenic viruses. 309

To test the mismatch tolerance of our Cas13b system against various 310 replication-competent SARS-CoV-2 viral strains, we transfected VERO cells with NT 311 gRNA, NCP-1 targeting gRNA (positive control), or 4 tiled gRNAs (10, 15, 20, 30) fully 312 matching the ancestral Spike sequence D614 (see the schematic illustration in Figure  313 5A & 5B). 48 hours post-infection, VERO cells expressing pspCas13-BFP and various 314 gRNAs were infected with either the ancestral or D614G mutant SARS-CoV-2, and 315 the viral loads in supernatants were quantified by RT-PCR 1h (initial viral input), 24h 316 and 48h post-infection ( Figure 5B ). The comparison of viral loads in the supernatant 317 of cells infected with either the ancestral or D614G in the control groups (NT) showed 318 7.7, 4.2, and 2.3-fold higher viral loads in the D614G samples at timepoints 1h, 24h, 319 and 48h, respectively ( Figure 5C, 5E & 5G) . These data revealed that the initial 320 D614G viral load used here was more than 7 times higher than the ancestral strain. 321

As anticipated, all SARS-CoV-2 targeting gRNAs tested showed no significant 322 viral suppression against the ancestral nor the D614G strains 1-hour post-infection. 323

The absence of viral suppression with targeting gRNAs at this early timepoint of 324 infection was anticipated because pspCas13b-mediated viral suppression requires 325 intracellular viral replication that had not yet occurred. 326

In the positive control groups, NCP-1 gRNA is used to target a fully matching 327 sequence within the Nucleocapsid RNA that is conserved in both ancestral and D614G 328 strains. Consistent with the data in Figure 2 and tested. This correlation highlights the predictive power of the virus-free model we 346 developed, and emphasises its utility to tractably screen and select the best 347 performing gRNAs. Overall, the data in Figure 5 provide strong evidence that 348 optimized single gRNAs are likely to retain efficacy against spontaneous point-349 mutations that arise during viral replication and can efficiently silence ancestral and 350 emerging SARS-CoV-2 mutants, including the D614G. 351

The remarkable capability of RNA viruses to adapt to selective host and environmental 353 pressure is highly dependent on their ability to generate genomic diversity through the 354 ( Figure 1, 2 & 3) . We demonstrated that a single gRNA can simultaneously silence 383 parental and emerging SARS-CoV-2 strains ( Figure 5) . The mismatch tolerance 384 mechanism shown here revealed that a single gRNA will likely remain effective against 385 future viral mutants that acquire de novo single-nucleotide indels as a result of genome 386 replication by the error-prone RdRP of SARS-CoV-2. 387

Given the high degree of tolerance to single-nucleotide mismatch and the use 388 of gRNA multiplexing, we postulate that a reprogrammed pspCas13b can act as a 389 universal tool to silence various SARS-CoV-2 strains that would escape conventional 390 antiviral therapeutics, including single monoclonal antibodies 7 or small inhibitor 391 molecules. A key step in enabling clinical translation of this approach will be to develop Data availability. All data are available in the main text and suppl materials. All key 406 plasmids generated in this study will be deposited in Addgene upon publication. The 407 bioinformatic code for the design of single-nucleotide tiled gRNAs and filtering 408 strategies will be made available upon request and will be published in a separate 409 manuscript. For gRNA cloning, a forward and reverse single-stranded DNA oligos 542 containing CACC and CAAC overhangs respectively, were ordered from Sigma 543 (100μM). 1.5μL of 100uM the forward and reverse DNA oligos were annealed in 47μL 544 annealing buffer (5ul NEB buffer 3.1 and 42μL H2O) by 5min incubation at 95C° and 545 slow cooldown in the heating block overnight. 1μL of the annealed oligos were ligated 546 with 0.04ng digested pspCAs13b gRNA backbone in 10μL of T4 ligation buffer (3 547 hours, RT). All pspCas13b gRNA spacer sequences used in this study are listed in the 548 Table below . 549

The original pspCas13b (addgene#103862) is a gift from Feng Zhang lab 22 . A new 551 pspCas13 plasmid was designed by fusing a 3xFlag-T2A-BFP tag to the Cas13 C-552 terminus using EcoRI and NheI enzymatic restriction. 5μg of pUC19 vector encoding 553 a Psp-Cas13b-3'end-3xFlag-T2A-BFP sequence was generated by DNA synthesis 554 (IDT). Psp-Cas13b-3'end-3xFlag-T2A-BFP and the original pC0046-EF1a-555

PspCas13b-NES-HIV plasmids were digested by EcoRI/NheI restriction enzymes (1 556 hour, 37C°), followed by column clean up with NucleoSpin™ Gel and PCR Clean-up 557

Kit (Macherey-Nagel). The digestion efficiency was verified by 1% agarose gel. The 558

Psp-Cas13b-3'end-3xFlag-T2A-BFP fragment with the correct size was gel purified 559

using NucleoSpin™ Gel and PCR Clean-up Kit. The two fragments were ligated using 560 T4 ligase (3 hours, RT), and transformed into Stbl3 chemically competent bacteria. 561

Positive clones were screened by PCR and Singer sequenced (AGRF, AUSTRALIA). 562

Cloning of SARS-CoV-2 Spike, Spike D614G, and Nucleocapsid cDNA. 563

A mammalian expression plasmid containing a codon-optimized sequence of the 564 Spike protein was obtained through Genscript plasmid sharing platform (Ref# 565 MC_0101087), and was a kind gift from Dr. Haisheng Yu lab. 566

The coding sequence of NCP and part of Spike D614G sequence was 567 designed according to the first SARS-CoV-2 genome 23 . The Genscript DNA synthesis 568 platform provided the two sequences that were subsequently cloned into MSCV-IRES-569 mcherry vector in frame with 3xHA tag using BamHI digestion, gel purification, and 570 ligation with T4 DNA ligase. The ligated product was transformed into chemically 571 competent bacteria (Top10) and positive clones were screened by PCR and Singer 572 sequencing (AGRF, AUSTRALIA). 573

TOP10 (for all gRNA, Spike, D614G Spike, and NCP cloning) and Stbl3 (for Cas13 575 cloning) bacteria were used for transformation. 5-10μL ligated plasmids were 576 transformed into 30 μL of chemically competent bacteria by heat shock at 42C° for 45 577 seconds, followed by 2min on ice. The transformed bacteria were incubated in 500μL 578 LB broth media containing 75μg/mL ampicillin for 1 hour at 37C° in a shaking incubator 579 (200 rpm). The bacteria were pelleted by centrifugation at 8,000 rpm for 1minute at 580 room temperature (RT), re-suspended in 100 μL of LB broth, and plated onto a pre-581 warmed 10 cm LB agar plate containing 75μg/mL ampicillin, and incubated at 37C° 582 overnight. Next day, single colonies were picked and transferred into bacterial starter 583 cultures and incubated for ~6 hours for mini-prep or maxi-prep DNA purification 584 according to the standard manufacturer's protocol. All gRNAs and pspCas13b clones 585 that are generated in this study were verified by Sanger sequencing (AGRF, 586 AUSTRALIA). P<0.05 is considered as statistically significant. 692

Guide RNA name gRNA Target/Description Sequence Figure  NT Non targeting gRNA TAGATTGCTGTTCTACCAAGTAATCCATCA Figure1 atgaacatccccgctctggtggaaaaccagaagaagtactttggcacctacagcgtgatggccatgctgaacgctcagaccgtgct  697  ggaccacatccagaaggtggccgatattgagggcgagcagaacgagaacaacgagaatctgtggtttcaccccgtgatgagccac  698  ctgtacaacgccaagaacggctacgacaagcagcccgagaaaaccatgttcatcatcgagcggctgcagagctacttcccattcct  699  gaagatcatggccgagaaccagagagagtacagcaacggcaagtacaagcagaaccgcgtggaagtgaacagcaacgacatct  700  tcgaggtgctgaagcgcgccttcggcgtgctgaagatgtacagggacctgaccaaccactacaagacctacgaggaaaagctgaa  701  cgacggctgcgagttcctgaccagcacagagcaacctctgagcggcatgatcaacaactactacacagtggccctgcggaacatg  702  aacgagagatacggctacaagacagaggacctggccttcatccaggacaagcggttcaagttcgtgaaggacgcctacggcaag  703  aaaaagtcccaagtgaataccggattcttcctgagcctgcaggactacaacggcgacacacagaagaagctgcacctgagcggag  704  tgggaatcgccctgctgatctgcctgttcctggacaagcagtacatcaacatctttctgagcaggctgcccatcttctccagctacaat  705  gcccagagcgaggaacggcggatcatcatcagatccttcggcatcaacagcatcaagctgcccaaggaccggatccacagcgaga  706  agtccaacaagagcgtggccatggatatgctcaacgaagtgaagcggtgccccgacgagctgttcacaacactgtctgccgagaa  707  gcagtcccggttcagaatcatcagcgacgaccacaatgaagtgctgatgaagcggagcagcgacagattcgtgcctctgctgctgc  708  agtatatcgattacggcaagctgttcgaccacatcaggttccacgtgaacatgggcaagctgagatacctgctgaaggccgacaag  709  acctgcatcgacggccagaccagagtcagagtgatcgagcagcccctgaacggcttcggcagactggaagaggccgagacaatg  710  cggaagcaagagaacggcaccttcggcaacagcggcatccggatcagagacttcgagaacatgaagcgggacgacgccaatcct  711  gccaactatccctacatcgtggacacctacacacactacatcctggaaaacaacaaggtcgagatgtttatcaacgacaaagagga  712  cagcgccccactgctgcccgtgatcgaggatgatagatacgtggtcaagacaatccccagctgccggatgagcaccctggaaattc  713  cagccatggccttccacatgtttctgttcggcagcaagaaaaccgagaagctgatcgtggacgtgcacaaccggtacaagagactg  714  ttccaggccatgcagaaagaagaagtgaccgccgagaatatcgccagcttcggaatcgccgagagcgacctgcctcagaagatcc  715  tggatctgatcagcggcaatgcccacggcaaggatgtggacgccttcatcagactgaccgtggacgacatgctgaccgacaccgag  716  cggagaatcaagagattcaaggacgaccggaagtccattcggagcgccgacaacaagatgggaaagagaggcttcaagcagatc  717  tccacaggcaagctggccgacttcctggccaaggacatcgtgctgtttcagcccagcgtgaacgatggcgagaacaagatcaccgg  718  cctgaactaccggatcatgcagagcgccattgccgtgtacgatagcggcgacgattacgaggccaagcagcagttcaagctgatgt  719  tcgagaaggcccggctgatcggcaagggcacaacagagcctcatccatttctgtacaaggtgttcgcccgcagcatccccgccaat  720  gccgtcgagttctacgagcgctacctgatcgagcggaagttctacctgaccggcctgtccaacgagatcaagaaaggcaacagagt  721  ggatgtgcccttcatccggcgggaccagaacaagtggaaaacacccgccatgaagaccctgggcagaatctacagcgaggatctg  722  cccgtggaactgcccagacagatgttcgacaatgagatcaagtcccacctgaagtccctgccacagatggaaggcatcgacttcaa  723  caatgccaacgtgacctatctgatcgccgagtacatgaagagagtgctggacgacgacttccagaccttctaccagtggaaccgca  724  actaccggtacatggacatgcttaagggcgagtacgacagaaagggctccctgcagcactgcttcaccagcgtggaagagagaga  725  aggcctctggaaagagcgggcctccagaacagagcggtacagaaagcaggccagcaacaagatccgcagcaaccggcagatga  726  gaaacgccagcagcgaagagatcgagacaatcctggataagcggctgagcaacagccggaacgagtaccagaaaagcgagaa  727  agtgatccggcgctacagagtgcaggatgccctgctgtttctgctggccaaaaagaccctgaccgaactggccgatttcgacggcg  728  agaggttcaaactgaaagaaatcatgcccgacgccgagaagggaatcctgagcgagatcatgcccatgagcttcaccttcgagaa  729  aggcggcaagaagtacaccatcaccagcgagggcatgaagctgaagaactacggcgacttctttgtgctggctagcgacaagagg  730  atcggcaacctgctggaactcgtgggcagcgacatcgtgtccaaagaggatatcatggaagagttcaacaaatacgaccagtgca  731  ggcccgagatcagctccatcgtgttcaacctggaaaagtgggccttcgacacataccccgagctgtctgccagagtggaccgggaa  732  gagaaggtggacttcaagagcatcctgaaaatcctgctgaacaacaagaacatcaacaaagagcagagcgacatcctgcggaag  733  atccggaacgccttcgatcacaacaattaccccgacaaaggcgtggtggaaatcaaggccctgcctgagatcgccatgagcatcaa  734  gaaggcctttggggagtacgccatcatgaagggatcccttcaactgcctccacttgaaagactgacactggactataaggaccacg  735  acggagactacaaggatcatgatattgattacaaagacgatgacgataagggcggcgggtccggaggagagggcagaggaagtc  736  tcctaacatgcggtgacgtggaggagaatcctggcccaatgagcgagctgattaaggagaacatgcacatgaagctgtacatgga  737  gggcaccgtggacaaccatcacttcaagtgcacatccgagggcgaaggcaagccctacgagggcacccagaccatgagaatcaa  738  ggtggtcgagggcggccctctccccttcgccttcgacatcctggctactagcttcctctacggcagcaagaccttcatcaaccacacc  739  cagggcatccccgacttcttcaagcagtccttccctgagggcttcacatgggagagagtcaccacatacgaggacgggggcgtgct  740  gaccgctacccaggacaccagcctccaggacggctgcctcatctacaacgtcaagatcagaggggtgaacttcacatccaacggcc  741  ctgtgatgcagaagaaaacactcggctgggaggccttcaccgagaccctgtaccccgctgacggcggcctggaaggcagaaacga  742  catggccctgaagctcgtgggcgggagccatctgatcgcaaacatcaagaccacatatagatccaagaaacccgctaagaacctc  743  aagatgcctggcgtctactatgtggactacagactggaaagaatcaaggaggccaacaacgagacctacgtcgagcagcacgag  744  gtggcagtggccagatactgcgacctccctagcaaactggggcacaagcttaattga atgttcgtgtttctggtgctgctgcctctggtgagctcccagtgcgtgaacctgaccacacggacacagctgccccctgcctacacca  751  acagcttcacaaggggcgtgtactaccccgacaaggtgtttagatctagcgtgctgcactccacacaggatctgtttctgcctttcttt  752  tctaacgtgacctggttccacgctatccacgtgtccggcaccaacggaacaaagaggttcgacaacccagtgctgccctttaacgat  753  ggcgtgtacttcgcctccaccgagaagtctaacatcatcagaggctggatctttggaaccacactggacagcaagacacagtccct  754  gctgatcgtgaacaacgccaccaacgtggtcatcaaggtgtgcgagttccagttttgtaacgatccattcctgggcgtgtactaccac  755  aagaacaacaagtcttggatggagagcgagtttcgcgtgtactcctctgccaacaactgtacatttgagtacgtgtcccagcccttcc  756  tgatggacctggagggcaagcagggaaacttcaagaacctgcgggagttcgtgtttaagaacatcgatggctactttaagatctact  757  ccaagcacaccccaatcaacctggtgcgcgacctgccacagggcttctctgccctggagccactggtggatctgcccatcggaatca  758  acatcaccaggtttcagacactgctggccctgcacagaagctacctgacaccaggcgacagctcctctggatggaccgctggagct  759  gctgcctactacgtgggctacctgcagccccggaccttcctgctgaagtacaacgagaacggaaccatcacagacgctgtggattg  760  cgccctggaccccctgtctgagaccaagtgtacactgaagagctttaccgtggagaagggcatctaccagacaagcaacttccggg  761  tgcagcctaccgagtccatcgtgcgctttcccaacatcacaaacctgtgcccttttggagaggtgttcaacgctacccgcttcgcctcc  762  gtgtacgcttggaaccggaagcgcatctccaactgcgtggccgactactctgtgctgtacaacagcgccagcttcagcaccttcaag  763  tgctacggcgtgagcccaacaaagctgaacgacctgtgctttaccaacgtgtacgctgattccttcgtgatcaggggagacgaggtg  764  cgccagatcgctcccggccagacaggaaagatcgctgactacaactacaagctgcctgacgatttcaccggctgcgtgatcgcctg  765  gaactctaacaacctggatagcaaagtgggcggaaactacaactacctgtacaggctgtttagaaagtctaacctgaagccattcg  766  agcgggacatctccacagagatctaccaggctggctctaccccatgcaacggagtggagggcttcaactgttacttccctctgcaga  767  gctacggattccagccaacaaacggcgtgggataccagccctaccgcgtggtggtgctgtcttttgagctgctgcacgctcctgctac  768  agtgtgcggaccaaagaagagcaccaacctggtgaagaacaagtgcgtgaacttcaactttaacggactgaccggcacaggagtg  769  ctgaccgagtctaacaagaagttcctgccttttcagcagttcggccgggacatcgccgataccacagacgctgtgcgcgaccctcag  770  accctggagatcctggatatcacaccatgctccttcggcggagtgtctgtgatcacaccaggaaccaacacaagcaaccaggtggc  771  cgtgctgtaccaggacgtgaactgtaccgaggtgcccgtggctatccacgccgatcagctgacccctacatggagggtgtactctac  772  cggcagcaacgtgttccagacaagagccggctgtctgatcggagctgagcacgtgaacaacagctacgagtgcgacatccctatcg  773  gcgccggaatctgtgcttcctaccagacccagacaaactccccaaggagagccaggtctgtggctagccagtccatcatcgcctac  774  accatgagcctgggcgccgagaactccgtggcttactccaacaactctatcgctatccctaccaacttcacaatctccgtgaccacag  775  agatcctgccagtgagcatgaccaagacatccgtggactgcacaatgtacatctgtggagattccaccgagtgctctaacctgctgc  776  tgcagtacggctctttctgtacccagctgaacagagccctgacaggaatcgctgtggagcaggacaagaacacacaggaggtgttc  777  gcccaggtgaagcagatctacaagaccccacccatcaaggactttggcggattcaactttagccagatcctgcccgatcctagcaa  778  gccatccaagaggtcttttatcgaggacctgctgttcaacaaggtgaccctggctgatgccggcttcatcaagcagtacggcgattgc  779  ctgggagacatcgctgccagagacctgatctgtgcccagaagtttaacggactgaccgtgctgcctccactgctgacagatgagatg  780  atcgctcagtacacatctgctctgctggccggcaccatcacaagcggatggaccttcggcgctggagctgccctgcagatcccctttg  781  ccatgcagatggcttacagattcaacggcatcggagtgacccagaacgtgctgtacgagaaccagaagctgatcgccaaccagttt  782  aactccgctatcggcaagatccaggactctctgagctccacagctagcgccctgggaaagctgcaggatgtggtgaaccagaacgc  783  tcaggccctgaacaccctggtgaagcagctgtctagcaacttcggcgccatctcctctgtgctgaacgatatcctgagcaggctgga  784  caaggtggaggctgaggtgcagatcgacaggctgatcacaggaagactgcagtccctgcagacctacgtgacacagcagctgatc  785  agggctgctgagatcagggcttctgccaacctggctgccaccaagatgagcgagtgcgtgctgggccagtccaagagagtggactt  786  ttgtggcaagggataccacctgatgagcttcccacagtccgcccctcacggagtggtgtttctgcacgtgacctacgtgccagctcag  787  gagaagaacttcaccacagctcccgccatctgccacgatggcaaggcccactttcctcgggagggcgtgttcgtgagcaacggaac  788  ccactggtttgtgacacagcgcaacttctacgagccacagatcatcaccacagacaacacattcgtgtccggcaactgtgacgtggt  789  catcggaatcgtgaacaacaccgtgtacgatcctctgcagccagagctggactcttttaaggaggagctggataagtacttcaaga  790  accacaccagccctgacgtggatctgggcgacatctctggaatcaacgccagcgtggtgaacatccagaaggagatcgaccggct  791  gaacgaggtggctaagaacctgaacgagtccctgatcgatctgcaggagctgggcaagtacgagcagtacatcaagtggccctgg  792  tacatctggctgggcttcatcgccggactgatcgctatcgtgatggtgaccatcatgctgtgctgtatgacaagctgctgttcctgcct  793  gaagggctgctgttcttgtggaagctgctgtaagtttgacgaggacgatagcgagcctgtgctgaagggcgtgaagctgcactacac  794  caagcttggatccggaagcggagctactaacttcagcctgctgaagcaggctggagacgtggaggagaaccctggacctatgagc  795  aagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccg  796  gcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccacc  797  ctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatg  798  cccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcg  799  acaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaacta  800  caacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggac  801  ggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctga  802  gcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcact  803  cacggcatggacgagctgtacaagtaa Suppl. Figure 2 

Suppl. Figure 3 Uncropped western blots in Figure 2D 

An interactive web-based dashboard to track 847 COVID-19 in real time

Developing covid-19 vaccines at 850 pandemic speed

Potently neutralizing and protective human antibodies against 853 SARS-CoV-2

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Discovery of SARS-CoV-2 antiviral drugs through large-scale 857 compound repurposing

Structural basis for inhibition of the RNA-dependent RNA 859 polymerase from SARS-CoV-2 by remdesivir

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 862 mutational escape seen with individual antibodies

Tracking Changes in SARS-CoV-2 Spike: Evidence that 865 D614G Increases Infectivity of the COVID-19 Virus

Structural and Functional Analysis of the D614G SARS-868

CoV-2 Spike Protein Variant

Spike mutation D614G alters SARS-CoV-2 fitness and 870 neutralization susceptibility

Global initiative on sharing all influenza data -872 from vision to reality

NextStrain: Real-time tracking of pathogen evolution

Effects of a major deletion in the SARS-CoV-2 genome on 877 the severity of infection and the inflammatory response: an observational 878 cohort study

Emerging SARS-CoV-2 mutation hot spots include a novel 880 RNA-dependent-RNA polymerase variant

Jumping back and forth: anthropozoonotic and 882 zoonotic transmission of SARS-CoV-2 on mink farms Affiliations

C2c2 is a single-component programmable RNA-887 guided RNA-targeting CRISPR effector

Diversity and evolution of class 2 CRISPR-Cas systems

RNA targeting with CRISPR-Cas13

Programmable Inhibition and Detection of RNA Viruses 893 Using Cas13

Development of CRISPR as an Antiviral Strategy to Combat 895 SARS-CoV-2 and Influenza

RNA editing with CRISPR-Cas13. Science (80-. )

A new coronavirus associated with human respiratory disease in 899 China

A highly conserved cryptic epitope in the receptor binding 901 domains of SARS-CoV-2 and SARS-CoV. Science (80-. )

Isolation and rapid sharing of the 2019 novel coronavirus

CoV-2) from the first patient diagnosed with COVID-19 in Australia

High-Resolution Structure of Cas13b and Biochemical 907 Characterization of RNA Targeting and Cleavage

The Molecular Architecture for RNA-Guided RNA Cleavage by 910 Cas13a

Structural Basis for the RNA-Guided Ribonuclease Activity of 912 CRISPR-Cas13d

Structure of replicating SARS-CoV-2 polymerase

Structure of the SARS-CoV nsp12 916 polymerase bound to nsp7 and nsp8 co-factors

CRISPR-Cas guides the future of genetic 919 engineering

The 921 SARS coronavirus nucleocapsid protein -Forms and functions

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA 924 binding domain reveals potential unique drug targeting sites

Mechanisms of viral mutation

Massively parallel Cas13 screens reveal principles for 929 guide RNA design

SARS-CoV and emergent coronaviruses: 931 Viral determinants of interspecies transmission

HIV-1 antiretroviral drug therapy

Transcriptome Engineering with RNA-Targeting Type VI-936

Two Distant Catalytic Sites Are Responsible for C2c2 RNase 938 Activities

Systemic 940 nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue 941 specific genome editing

Determination of 50% endpoint titer using a simple 944 formula

 Supplementary Table 1 . Single-nucleotide increment spacer sequence (DNA) of gRNAs covering the entire genome of SARS-CoV-2. The 30-nt spacer sequences were generated using inhouse script written in Python and are complementary to the target RNA. For each gRNA, we provide the matching location in the SARS-CoV-2 genome, the predicted secondary structure of the spacer and target sequences, and the corresponding predicted minimum free energy (kcal/mol). The data in this table are unfiltered and unranked. Table 2 . Single-nucleotide increment spacer sequence of gRNAs covering the entire genome of SARS-CoV-2 are listed. The 30-nt spacer sequences are complementary to the target, and were generated using inhouse code written in Python. For each gRNA, we provide the matching coordinate in the SARS-CoV-2 genome, the predicted secondary structure of the spacer and target sequences, and the predicted minimum free energy (kcal/mol). The data in this table are filtered to remove spacer sequences that include 4 or more successive T residues that would prematurely terminate Pol III-driven spacer transcription and generate non-functional gRNAs. The gRNAs are ranked based on predicted secondary structures in the target and spacer sequence. Table 3 . Top scoring 839 gRNAs with a predicted open secondary structure in the spacer and target sequences. These gRNAs are designed to fully base-pair with various regions of SRAS-CoV-2 genome and are predicted to achieve high silencing efficiency, given that Cas13b efficacy is governed by target accessibility.

All gRNAs used in this study are listed.

Bioinformatics pipeline for the design and selection of pspCas13b gRNAs that are predicted to achieve high silencing efficiency. gRNAs are tiled across the entire RNA genome of SARS-CoV-2 with single-nucleotide increments. gRNAs harbouring 4 or more successive T residues are removed to avoid premature termination of Pol III-driven gRNA transcription, and the top 839 gRNAs with predicted open secondary structure in the spacer and target are selected. (B) Predicted secondary structure of the spacer (upper panels) and its target sequence (lower panels) in the top scoring and lowest scoring gRNAs in Suppl. Table 1 . The RNA secondary structures were generated using the RNAfold program 1 (ViennaRNA webservices). The top scoring gRNA shows a predicted open structure for both the spacer and the target, while both structures of the lowest scoring gRNA exhibit high probability of folding into stem-loop that may impair gRNA loading into pspCas13b and target accessibility. Figure 2 . Dose-dependent silencing of NCP transcript with nontargeting gRNA (NT), wildtype gRNA1 (WT), gRNA1 harbouring 1-3, 1-6, or 1-9 nucleotides mismatches at the 5'end of the spacer. Data are normalized mean fluorescence and errors are SD from 4 different field of views. N=1.

The dose-dependent silencing shows that the silencing efficiency is dependent on the degree of base-pairing between the spacer and the target. The reduction in the silencing efficiency is proportional to the number of mismatches within the spacertarget RNA-RNA duplex. For instance, with 0.8ng of WT, 1-3, 1-6, and 1-9 nucleotides mismatches gRNAs we achieved 87%, 57%, 34%, and 5% silencing efficiency, respectively. Thus, demonstrating the dependency between the spacer-target basepairing and silencing efficiency.